Table 2.
New treatment approaches for AS and their current status
| Therapy | Target | Status |
|---|---|---|
| CT-P13 (infliximab biosimilar) | Anti-TNF | Approved |
| SB4 (etanercept biosimilar) | Anti-TNF | Approved |
| Secukinumab | Anti-IL-17A | Approved |
| Ixekizumab | Anti-IL-17A | Under investigation |
| Brodalumab | Anti-IL-17R | Not approved |
| Ustekinumab | Anti-IL-12/IL-23 | Not approved |
| ABT-122 | Anti-IL-17A/TNF-α | Under investigation. Successful Phase II clinical trials |
| COVA322 | Anti-IL-17A/TNF-α | Not approved |
| CBP30 | CBP/p300 bromodomain inhibition | Future trials announced |
| Sarilumab | Anti-IL-6Rα | Not approved |
| Tofacitinib | JAK inhibitor | Under investigation. Successful Phase II clinical trials |
| BCD-085 | IL-17A inhibitor | Clinical Phase II. Ongoing |
| Bimekizumab | IL-17A, −17F inhibitor | Clinical Phase II. Ongoing |
| Tildrakizumab | IL-23 inhibitor | Clinical Phase II. Planned |
| Risankizumab | IL-23 inhibitor | Clinical Phase II. Completed |
| Tofacitinib | panJAK inhibitor | Clinical Phase II. Completed |
| Upadacitinib | JAK-1 inhibitor | Clinical Phase IIb/III. Recruiting |
| Filgotinib | JAK-1 inhibitor | Clinical Phase II. Recruiting |
| Apremilast | Phosphodiesterase 4 inhibitor | Clinical Phase III. Ongoing |
Abbreviation: AS, ankylosing spondylitis.